TroVax (5T4 cancer vaccine)

09/01/2006 - "In a pre-clinical murine model, the recombinant virus (TroVax) induces protection against challenge with CT26-h5T4 (a syngeneic tumor line expressing h5T4). "
01/01/2012 - "This article will discuss the clinical background of RCC, the rationale for TroVax development, results of several TroVax clinical trials and future directions for optimizing TroVax therapy in patients with RCC and other cancers."
10/01/2010 - "Herein, we review the results of these clinical studies, discuss the lessons learned through these trials and provide some insight into the future development of TroVax as a cancer vaccine."
10/01/2002 - "In active treatment studies, inoculation with MVA-h5T4 was able to treat established CT26-h5T4 lung tumor and to a lesser extent B16.h5T4 s.c. "
12/01/2012 - "Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax)."

11/01/2010 - "Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients."
01/01/2012 - "With minimal side effects and the ability to produce a strong immunogenic response, TroVax (MVA-5T4) is a viable addition to the treatment of prostate cancer."
01/01/2012 - "TroVax has been demonstrated to be safe and highly immunogenic, both as monotherapy and in combination with other standard of care therapies in colorectal, renal cell, and prostate cancer. "
01/01/2012 - "Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer."
01/01/2011 - "This review will discuss the rationale for immunotherapy in prostate cancer and describe preclinical and limited clinical data in prostate cancer for the MVA-5T4 (TroVax(®)) vaccine."

06/01/2011 - "Patients with renal cancer and requiring first-line treatment for metastatic disease were randomized 1:1 to receive MVA-5T4 (TroVax(®)) or placebo alongside Sunitinib, IL-2 or IFN-α in a multicentre phase III trial. "
05/01/2009 - "Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha."

10/01/2010 - "TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development."
05/01/2009 - "The attenuated strain of vaccinia virus, modified vaccinia Ankara, has been engineered to express 5T4 (TroVax). "
09/01/2007 - "This paper reviews the development of a novel immunotherapeutic vaccine comprising the highly attenuated modified vaccinia ankara virus encoding 5T4 (MVA-5T4, aka TroVax). "
05/01/2006 - "Subsequently, we have demonstrated that HLA-Cw7-positive colorectal cancer patients vaccinated with a recombinant vaccinia viral vector encoding 5T4 (TroVax) are capable of mounting a strong IFN-gamma ELISPOT response to this novel CTL epitope. "
01/01/2013 - "MVA-5T4 (TroVax(®)) is a novel vaccine combining the tumor-associated antigen 5T4 to an engineered vector-modified vaccinia Ankara (MVA). "

01/01/2014 - "TroVax in colorectal cancer."
07/01/2008 - "TroVax was administered to 19 patients with metastatic colorectal cancer. "
08/01/2007 - "TroVax was administered to 17 patients with metastatic colorectal cancer. "
06/01/2006 - "TroVax was given to 22 patients with metastatic colorectal cancer. "
10/01/2009 - "Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)."